Tilray stock rises 29% on plans to import cannabis to U.S. for clinical …

The U.S. Drug Enforcement Administration has signed off on cannabis cultivator Tilray Inc.’s plan to import a marijuana product from Canada to test its effectiveness at treating a disorder that affects millions of Americans.

The DEA’s signoff is the final regulatory hurdle Tilray

TLRY, -30.25%

 needed for a clinical trial of the medication’s effects on essential tremor, a neurological movement disorder. Tilray, the first pot producer to go public on Nasdaq, is testing for marijuana’s potential efficacy for

... read more at: https://www.marketwatch.com/story/tilray-to-import-cannabis-to-us-for-clinical-trial-2018-09-18